What to expect this next month now that we sold 1.8 million
What to expect this next month now that we sold 1.8 million shares plus 3/4 warrants for a total of 3.15 million shares not including the Paulson Charge of what 12%. The big questions is will around a half million in funding last us a month with no trials in progress?
Was this just a bandaid to get us to the end of a negotiation? Or will the BOD be smart enough to set up the next round and just release the 700mg Nash results that many investors including my self believe that are spectacular? (The old Recknor drew us in on being excited about the Nash results.) Or will this be a multi news release when it happens? Like here are the Nash results and since they were such awe inspiring we partnered with blank to start a phase 3 trial with all the necessary bio markers that small biotechs only dream of.
When it comes to financing and only having a small sale of 1.8 million when we have so much more to sell for necessary day to day operations and any debt to pay down. This small sale looks like something is about to happen with great news. Or why so little shares being sold? This is what I believe should or could be a news release of some kind very soon. Should we list all the possibilities of news?
1. Nash 700mg results.
2. Nash partner for a phase 3 w/upfront monies
3. mTNBC partner for a phase 3 w/upfront monies.
4. New CEO with all the experience we dream of…
5. Announce that ANVISA restarts our trials.
6. The FDA has been notified that Anvisa approved.
7. New timeline to safety aggregate completion. With approved HIV mono restart of phase 3.
8. Resubmission of BLA as soon as safety aggregate is complete and audit shows all verifiable information has been harvested properly and is acceptable. With a firm new date of submission.
9. That a partnership monies has allowed us to start our FDA approved Long Covid Trial.
If I have left anything of our wish list… feel free to add any additional catalysts that might be coming up.
The big question is which one is the first to bump the stock price? Hmmm? Wouldn’t it be nice if all of them hit in the next 3 months? Oh to dream! As Shelly often says… Let’s go!!!
3
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A Bra Revolution or Just Another Launch? I'll admit it, lingerie isn't the usual breakfast discussion for me, but Vanity Fair Lingerie's move with their new Flawlessly Smooth™ Bra piqued my interest. Announced in Bowling Green, Kentucky, on November 2, 2026, and set against the lavish backdrop of an upcoming New York City event cohosted by Cosmopolitan, it's less about...
Continue Reading
Lighting a Fire Under Complacency Elections often bring out the big dogs, but rarely do you see a grassroots campaign like Extreme Weather Survivors’ 'Stolen Summers' making such ripples. Rallying from New York to North Carolina and everywhere in between, this campaign has been a clarion call for communities ravaged by Mother Nature's fury. And let's face it, the...
Continue Reading
Another Day, Another Big Hire in D.C. You'd think the revolving doors at these law firms were tied to Wall Street's cycles. Latham & Watkins, one heavyweight in the legal arena, is pulling a classic power move, snapping up Steven Johnson for their Washington, D.C. office. He ain't just some guy off the street; Johnson's got a résumé that reads like a textbook on federal...
Continue Reading
A Veteran's Task in a New Territory Piling onto its international ambitions, XPENG has roped in Lee Man-sik, a seasoned auto industry professional, to break into South Korea. South Korea isn’t just another market—it’s one of the toughest stages for the automotive industry. The customers there are sharp, with a keen eye for tech and quality. So XPENG, trading under...
Continue Reading
Financial Milestones and Market Insights Boy, if you're not watching TETRA Technologies (NYSE:TTI) right now, you're probably missing out on a real barnstormer of a financial report. The numbers are looking chalkboards-be-damned stellar! They’ve just notched their finest third quarter in a decade, bringing in revenues through the roof at $168 million—an impressive 10%...
Continue Reading
Looking Ahead to Protalix's Q3 Revelation Nobody's pretending it's a cakewalk to stay ahead in the biopharma sector, especially when you're tangoing with the unpredictable world of rare disease therapeutics. But here we are, with Protalix BioTherapeutics scheduling their third-quarter financial results announcement for November 10, 2026. If you've been tracking them—or...
Continue Reading
SIMPLAAFY Trial Makes Waves in Cardiac Care Alright, let's dig into the heart of the matter—pun fully intended. Boston Scientific (NYSE:BSX) just rolled out some head-turning results from their SIMPLAAFY study, which evaluates the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device. What’s so special, you ask? Well, it’s all about simplifying the post-surgery...
Continue Reading
MIAX's Strategic Move Towards Binary Options Ah, that's something that might just shake things up a bit. On November 3rd, 2026, MIAMI International Holdings (NYSE: MIAX) made the headlines by filing with the SEC to offer cash-settled binary index options. Now, if you're not new to the trading game, you know that anything involving SEC registration gets the blood pumping....
Continue Reading
The Future of Drug Development: AI's New Role When it comes to pharmaceutical R&D, Some outfits are playing pin the tail on the donkey, but Differentia Bio over here is sharpening the pin with some futuristic gadgetry. Yep, they're jazzing up the game with AI-powered digital twins, building lifelike disease environments that predict therapeutic outcomes with precision...
Continue Reading
A Big Play in the Valve Game Straight out of the industrial playbook, Platinum Equity swoops in with its latest acquisition of Warren Valve, yanking it from the clutches of Allied Group. It's not every day you see a move like this in the flow control world. Yeah, you heard that right—flow control. The kind of business that’s all about ensuring the right stuff gets to...
Continue Reading
Top 5 Most Recently Viewed Articles
BOXX Insurance Embraces Growth in the U.S. Market BOXX Insurance is strategically enhancing its footprint in the U.S. market by appointing key leadership positions aimed at innovation within the cyber insurance space. This forward-thinking global insurtech is committed to delivering unique solutions tailored for both businesses and consumers. The expansion signifies a...
Continue Reading
Celleste Bio™ Achieves Landmark Cocoa Butter Production Celleste Bio™, an innovative cocoa technology company, has proudly announced a groundbreaking milestone in transforming the cocoa supply chain. The firm has unveiled its first-ever chocolate grade cocoa butter produced using cutting-edge plant cell culture technology, making waves in the agro-technological...
Continue Reading
Understanding VINCI's Share Capital and Voting Rights Total VINCI, a prominent French public limited company, is recognized for its significant role in infrastructure and construction. With a robust share capital totaling €1,474,737,915.00, the company's extensive operational framework has positioned it as a leader in its sector. Share Structure Overview As of the...
Continue Reading
Rezolve Ai's Daniel Wagner Advocates for UK AI Advancement In a significant announcement, Daniel Wagner, CEO and founder of Rezolve Ai (NASDAQ: RZLV), expressed strong support for the UK government's initiative to establish a National Data Library. This decision aims to enhance access to high-quality data for developers, a move Wagner characterizes as a pivotal moment for...
Continue Reading
Future Innovations in Art and Technology The China (Hangzhou) Art and Technology Biennale recently launched at the Yuhang Art Museum, serving as a significant platform for cultural exchange and artistic expression. This remarkable event, organized by the China Academy of Art (CAA) along with various art institutions and governmental bodies, showcases a diverse range of...
Continue Reading